RAPS and National University of Singapore Launch Regulatory Affairs Graduate Certificate Program
RAPS and the National University of Singapore have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs program.
The Regulatory Affairs Professionals Society (RAPS) and the National University of Singapore (NUS) have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs (MDRA) program. The program is intended for Singapore-based regulatory professionals, and was developed in partnership with the government of Singapore to cultivate an industry-ready regulatory workforce.
“Singapore has become an important center for biomedical research and business today,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE. “This program will be the first to offer instruction specifically designed to develop the medical device regulatory knowledge that is in high demand by the global companies located there.”
The MDRA program builds the foundational knowledge, critical thinking and application skills required of regulatory professionals. The curriculum will be delivered through a combination of online training, interactive seminars, peer interaction and case-based learning, and will cover regulations of ASEAN nations, China, the Asia-Pacific region, the US and Europe.
The program draws on the teaching and research excellence of NUS’ biomedical engineering faculty and the real world expertise of RAPS’ renowned regulatory leaders from around the world.
Enrollment is open from now until 8 August. Visit www.bioeng.nus.edu.sg/edu/mdra.html for full program details and application information, or contact the RAPS Pan-Asia office at [email protected] or Tel: +65 6496 5507.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
